← Back to Search

Primary hyperparathyroidism for Primary Hyperparathyroidism

Phase 2
Waitlist Available
Led By Donald W Anderson, MD, FRCSC
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 weeks
Awards & highlights

Study Summary

The overall sensitivity and specificity of 11C-MET PET/CT is superior to 18F-FDG PET/CT and conventional SPECT-CT for the detection of abnormal parathyroid glands.

Eligible Conditions
  • Primary Hyperparathyroidism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~patient will undergo the scans at baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and patient will undergo the scans at baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To compare the sensitivity of 11C-MET PET/CT, SPECT-CT and 18F-FDG PET/CT in the detection of pathologic parathyroid glands in patients with primary hyperparathyroidism
To compare the specificity of11C-MET PET/CT, SPECT-CT and 18F-FDG PET/CT in the detection of pathologic parathyroid glands in patients with primary hyperparathyroidism
Secondary outcome measures
To evaluate the safety profile of 11C-MET PET/CT.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Primary hyperparathyroidismExperimental Treatment3 Interventions
Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,418 Previous Clinical Trials
2,467,068 Total Patients Enrolled
British Columbia Cancer AgencyOTHER
171 Previous Clinical Trials
90,461 Total Patients Enrolled
Donald W Anderson, MD, FRCSCPrincipal InvestigatorUniversity of British Columbia; Vancouver General Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues
2014. "11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01783002.
All > Thyroid
~5 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top